Voting Rights and Shares Capital of the Company
Rhea-AI Summary
Nanobiotix (Ticker: NBTX) reported its share and voting-rights counts as of December 31, 2025 in accordance with French disclosure rules.
The company shows 48,410,068 shares outstanding and a total theoretical number of voting rights of 50,109,170, with 50,087,052 exercisable voting rights.
Positive
- None.
Negative
- None.
News Market Reaction – NBTX
In the Jan 14 session, NBTX gained 0.70%, reflecting a mild positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 17 | Voting rights update | Neutral | +3.1% | Disclosure of November 30, 2025 voting rights and share capital data. |
| Dec 15 | Index inclusion | Positive | -1.6% | Announcement of joining CAC Mid 60 and SBF 120 indices. |
| Nov 24 | Quarterly update | Positive | +5.1% | Q3 2025 operational, financial update and 2026 clinical outlook. |
| Nov 14 | Voting rights update | Neutral | +2.6% | Disclosure of October 31, 2025 voting rights and share capital. |
| Nov 13 | Platform advancement | Positive | +2.6% | Curadigm Nanoprimer IP expansion, data presentation, and collaborations. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Administrative voting-rights updates have often seen positive price reactions despite neutral content, while operational and index-related news show a mix of aligned and divergent moves.
Over the last few months, NANOBIOTIX issued several administrative and strategic updates. Routine voting rights disclosures on Oct 31, 2025 and Nov 30, 2025 coincided with modest share price gains despite neutral content. Strategic news included admission to the CAC Mid 60 and SBF 120 indices and a Q3 2025 update featuring a $50 million royalty financing and cash visibility into early 2028. Platform progress for the Curadigm Nanoprimer was also highlighted. Today’s voting rights update fits the recurring pattern of French law-driven share capital disclosures.
Key Terms
isin code financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Jan. 13, 2026 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| December 31, 2025 | 48,410,068 | 50,109,170 | 50,087,052 |
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
________________________________
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Contacts
| Nanobiotix | |
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com |
| Media Relations | |
| France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com |
Attachment
- 2026-01-13 -- NBTX -- Voting Rights & Shares Capital -- FINAL
